| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA921: Ruxolitinib for treating polycythaemia vera |
|
Medicine details |
|
| Medicine name | ruxolitinib (Jakavi®) |
| Formulation | 5 mg, 10 mg, 15 mg, 20 mg tablet |
| Reference number | 888 |
| Indication | Treatment of adults with polycythaemia vera who are resistant to or intolerant of hydroxyurea |
| Company | Novartis Pharmaceuticals UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 03/03/2015 |
| NICE guidance | |